NMDSG10B. A multicentre open randomized phase II study of the efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q). Read more

NMDSG10A. A pilot phase I dose finding safety study of a Thrombopoietin-receptor agonist, Eltrombopag, in patients with Myelodysplastic syndrome treated with Azacitidine (NMDSG10A). Read more

NMDSG08A. Clinical and biological evaluation of azacitidine in transfusion-dependent patients with low and intermediate-1 risk MDS, and low-risk CMML, who are either refractory to or not eligible for treatment with erythropoietin +/- G-CSF. Read more

EU MDS Registry. A prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes. (EU MDS Registry) Read more

NMDSG07A. A multicentre phase II study of the efficacy and safety of lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) or monosomy 5. (NMDSG07A) Read more